Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double‐blind, placebo‐controlled, phase III trial

2008592 citationsJournal Article

Authors

Golimumab was effective and well tolerated in a large cohort of patients with AS during a 24-week study period.

Good health and well-being

Published in: Arthritis & Rheumatism

Volume 58, Issue 11, pp. 3402-3412

Field-Weighted Citation Impact: 21.18